ArticleCureus2025
Successful Autologous Blood Patch Pleurodesis in a Case of a Refractory Primary Spontaneous Pneumothorax.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autologous blood patch pleurodesis (ABPP) is a novel therapeutic option for persistent/refractory pneumothorax (PTX) in patients who fail to respond to the initial thoracostomy procedure. Previous evidence from the literature suggests its successful implementation in secondary spontaneous PTX. We present our experience with autologous blood pleurodesis being used successfully in a primary spontaneous PTX. It also highlights the use of autologous blood pleurodesis in failed talc pleurodesis. We present a 33-year-old gentleman with a complex cardiac history who developed a large left-sided primary spontaneous PTX. He was initially treated with a chest drain. He then underwent chemical pleurodesis with talc, as the PTX was unresolved despite having a chest drain inserted for over five days. It was discussed with the cardiothoracic team, but due to his complex cardiac history and poor cardiac functional status (ejection fraction of 25%), the surgical team deemed him not safe for any surgical intervention. Talc pleurodesis failed in the resolution of the PTX. Therefore, autologous blood pleurodesis was performed, which showed complete resolution within 24 hours. This case highlights the potential effectiveness of ABPP for persistent PTX in primary spontaneous PTX.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.